Prime Medicine Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
PRME$4.30-7.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows F-
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year Ended December 31, | ||
|---|---|---|
| (in thousands) | 2024 | 2023 |
| Cash flows used in operating activities: | ||
| Net loss | $(195,882) | $(198,133) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 26,068 | 13,910 |
| Non cash lease expense | 12,355 | 12,788 |
| Depreciation expense | 6,128 | 4,653 |
| Change in fair value of short-term investment — related party | 484 | 2,382 |
| Loss on disposal of property and equipment | — | 28 |
| Amortization of premiums and discount on short-term investments | (3,094) | (3,408) |
| Deferred income taxes | — | (279) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (15,859) | (9,455) |
| Accounts payable | (5,257) | 9,140 |
| Accrued expenses and other current liabilities | 1,843 | 1,758 |
| Accrued settlement payment — related party | (13,500) | 13,500 |
| Deferred revenue — related party | 70,310 | — |
| Lease liability | (6,461) | (12,296) |
| Net cash used in operating activities | (122,865) | (165,412) |
| Cash flows provided by investing activities: | ||
| Maturities of investments | 204,200 | 132,556 |
| Purchases of investments | (129,449) | (104,951) |
| Purchases of property and equipment | (7,294) | (8,724) |
| Return (payment) of security deposit | 1,000 | (170) |
| Net cash provided by investing activities | 68,457 | 18,711 |
| Cash flows provided by financing activities: | ||
| Proceeds from follow-on offering, net of issuance costs | 132,055 | — |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | 18,800 | — |
| Proceeds from issuance of common stock under the BMS Securities Purchase Agreement — related party | 38,081 | — |
| Proceeds from research and development funding liability | 6,000 | — |
| Proceeds from ESPP offerings | 837 | — |
| Net proceeds from stock option exercises | 103 | 655 |
| Net cash provided by financing activities | 195,876 | 655 |
| Net change in cash, cash equivalents, and restricted cash | 141,468 | (146,046) |
| Cash, cash equivalents, and restricted cash at beginning of period | 55,070 | 201,116 |
| Cash, cash equivalents, and restricted cash at end of period | $196,538 | $55,070 |
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year Ended December 31, | ||
|---|---|---|
| (in thousands) | 2024 | 2023 |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash, cash equivalents, and restricted cash at end of period | $196,538 | $55,070 |
| Less: restricted cash | 14,062 | 13,496 |
| Total cash, and cash equivalents | $182,476 | $41,574 |
| Supplemental cash flow information: | ||
| Right-of-use assets obtained in exchange for new operating lease liabilities | $44,935 | $3,265 |
| Decrease in right-of-use assets due to lease termination | $— | $6,081 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Purchases of property and equipment included in accounts payable and accrued expenses | $1,154 | $575 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.